Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xidike (uridine polyphosphate peptide) plus chemotherapy in advanced breast cancer and NSCLC
CTR20140557Phase 4Active
- Sponsor
- Hefei Yongsheng Pharmaceutical
- Start
- Sep 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of uridine polyphosphate peptide in breast cancer, non-small cell lung cancer (NSCLC), sponsored by Hefei Yongsheng Pharmaceutical. Started Sep 2014; status: active.
02
Drugs
uridine polyphosphate peptide
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20140557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140557.